copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Home - TuHURA We are a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy Through our leading IFx technology, we are developing personalized innate immune agonist to overcome tumor resistance to immunotherapies like checkpoint inhibitors
Investors - TuHURA TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy TuHURA’s lead innate immune response agonist candidate, IFx-2 0, is designed to overcome primary resistance to checkpoint inhibitors
TuHURA Biosciences Inc (HURA) Stock Price News - Google Get the latest TuHURA Biosciences Inc (HURA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions
TuHURA Biosciences Completes Merger Transaction with Kintara . . . TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2 0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma
TuHURA Biosciences (HURA) Stock Price Overview - Stock Analysis TuHURA Biosciences, Inc , a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies The company’s lead product candidate includes IFx2 0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors
TuHURA Biosciences, Inc. Enters into Definitive Merger . . . Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA’s late stage pipeline Targeting Phase 2a b trial with KVA12123 in mutated NPM1 AML in 2025 Cross product and technology synergies build on TuHURA’s therapeutic focus on overcoming primary and acquired resistance to cancer immunotherapy
About - TuHURA TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy TuHURA’s lead innate immune response agonist candidate, IFx-2 0, is designed to overcome primary resistance to checkpoint inhibitors